Nine Drugmakers to Slash U.S. Drug Prices

President Donald Trump has announced agreements with nine pharmaceutical companies, marking the latest in a series of deals aimed at lowering drug prices for some Americans in exchange for a three-year reprieve from threatened tariffs, Rachel Cohrs Zhang reported for Bloomberg News.

Roche Holding AG’s Genentech unit is one of the companies that have struck deals. (Photo: Genentech)

With the latest commitments, 14 of the 17 drugmakers targeted by Trump earlier this year have agreed to lower prices for Medicaid beneficiaries, sell discounted medicines directly to consumers, and launch new drugs in the U.S. at the same prices charged abroad.

“American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event at the Oval Office.

The companies that have struck deals include Roche Holding AG’s Genentech unit, Novartis AG, Bristol-Myers Squibb Co., Gilead Sciences Inc., Boehringer Ingelheim, Amgen Inc., GSK Plc, Sanofi, and Merck & Co.

These agreements mirror earlier pacts reached this year with Pfizer Inc. and AstraZeneca Plc.

The remaining three companies — AbbVie Inc., Johnson & Johnson, and Regeneron Pharmaceuticals Inc. — have yet to finalize agreements but confirmed they are currently in talks with the White House.

Trump said all three must still offer price concessions to avoid tariffs.